-
公开(公告)号：US20110244004A1
公开(公告)日：2011-10-06
申请号：US13161097
申请日：2011-06-15
IPC分类号： A61K31/496 , A61K9/14 , A61P31/10
CPC分类号： A61K31/496 , A01N43/653 , A61K9/0095 , A61K9/10 , A01N25/30 , A01N25/10 , A01N25/04 , A01N2300/00
摘要： A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
摘要翻译： 公开了一种包含抗真菌有效量的由化学结构式I表示的微粉化化合物的液体悬浮液：至少一种增稠剂，非离子表面活性剂和药学上可接受的液体载体。
-
公开(公告)号：US06916941B2
公开(公告)日：2005-07-12
申请号：US10403453
申请日：2003-03-31
申请人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
发明人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
IPC分类号： A61K9/14 , A61K9/20 , A61K9/28 , A61K9/48 , A61K31/343 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/36 , A61K47/38 , A61P25/24 , A61P43/00 , C07D307/87 , C07D307/78
CPC分类号： C07D307/87 , A61K9/2054 , A61K9/2095 , Y10T428/2982
摘要： Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
摘要翻译： 公开了具有至少40μm的粒度的草酸艾司西酞普兰的结晶颗粒。 还公开了制备所述结晶颗粒的方法和包含所述结晶颗粒的药物组合物。
-
公开(公告)号：US20120004318A1
公开(公告)日：2012-01-05
申请号：US13233381
申请日：2011-09-15
申请人： Suneel K. Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Shashank Mahashabde
发明人： Suneel K. Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Shashank Mahashabde
CPC分类号： A61K31/13 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K47/38 , Y02A50/411
摘要： The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
摘要翻译： 本发明提供每天一次给药的药物组合物，其含有选自美金刚和美金刚的药学上可接受的盐中的至少一种治疗活性成分和药学上可接受的聚合物基质载体。 当所述剂型暴露于水溶液时，本发明的剂型使治疗活性剂的释放持续约4至约24小时。 在所述形式进入使用环境之后，其中所述剂型在所述使用环境中进入约6小时至约12小时后具有大于约80％的溶解速率。
-
公开(公告)号：US20110046232A1
公开(公告)日：2011-02-24
申请号：US12888513
申请日：2010-09-23
IPC分类号： A61K31/13 , C07C211/38 , A61P25/28 , A61P25/00
CPC分类号： A61K31/13 , A61K9/0053 , A61K9/0056 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K9/7007 , A61K47/10 , A61K47/32 , A61K47/40 , Y02A50/411
摘要： Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.
摘要翻译： 提供口服溶解制剂，例如包含美金刚的片剂（ODT）和膜（ODF）和治疗病症的方法，包括儿童期行为障碍和阿尔茨海默氏病。 本发明的口服溶解制剂可用于治疗各种病症，但特别适用于治疗儿童行为障碍，例如自闭症谱系障碍或组合型注意力缺陷/多动障碍（ADHD），并且还可治疗患有老年患者 来自阿尔茨海默病。
-
公开(公告)号：US20080305164A1
公开(公告)日：2008-12-11
申请号：US12196812
申请日：2008-08-22
申请人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
发明人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
IPC分类号： A61K9/48 , A61K9/20 , A61K9/28 , C07D307/87
CPC分类号： C07D307/87 , A61K9/2054 , A61K9/2095 , Y10T428/2982
摘要： Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
摘要翻译： 公开了具有至少40μm的粒度的草酸艾司西酞普兰的结晶粒子。 还公开了制备所述结晶颗粒的方法和包含所述结晶颗粒的药物组合物。
-
公开(公告)号：US20060051416A1
公开(公告)日：2006-03-09
申请号：US11155330
申请日：2005-06-16
申请人： Suneel Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra Dedhiya , Shashank Mahashabde
发明人： Suneel Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra Dedhiya , Shashank Mahashabde
CPC分类号： A61K31/13 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K47/38 , Y02A50/411
摘要： The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
摘要翻译： 本发明提供每天一次给药的药物组合物，其含有选自美金刚和美金刚的药学上可接受的盐中的至少一种治疗活性成分和药学上可接受的聚合物基质载体。 当所述剂型暴露于水溶液时，本发明的剂型使治疗活性剂的释放持续约4至约24小时。 在所述形式进入使用环境之后，其中所述剂型在进入所述使用环境后经过约6小时至约12小时后具有大于约80％的溶解速率。
-
公开(公告)号：US08263600B2
公开(公告)日：2012-09-11
申请号：US13161097
申请日：2011-06-15
IPC分类号： A61K31/497
CPC分类号： A61K31/496 , A01N43/653 , A61K9/0095 , A61K9/10 , A01N25/30 , A01N25/10 , A01N25/04 , A01N2300/00
摘要： A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
摘要翻译： 公开了一种包含抗真菌有效量的由化学结构式I表示的微粉化化合物的液体悬浮液：至少一种增稠剂，非离子表面活性剂和药学上可接受的液体载体。
-
公开(公告)号：US07420069B2
公开(公告)日：2008-09-02
申请号：US11053641
申请日：2005-02-07
申请人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
发明人： Troels Volsgaard Christensen , Ken Liljegren , Michiel Onne Elema , Lene Andresen , Shashank Mahashabde , Sebastian P. Assenza
IPC分类号： C07D307/78 , A61K31/34
CPC分类号： C07D307/87 , A61K9/2054 , A61K9/2095 , Y10T428/2982
摘要： Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
摘要翻译： 公开了具有至少40μm的粒度的草酸艾司西酞普兰的结晶颗粒。 还公开了制备所述结晶颗粒的方法和包含所述结晶颗粒的药物组合物。
-
公开(公告)号：US20070270500A1
公开(公告)日：2007-11-22
申请号：US10578765
申请日：2004-11-05
申请人： Mahendra Dedhiya , Shashank Mahashabde , Yan Yang , Anshu Goel , Erhard Seiller , Bernhard Hauptmeier
发明人： Mahendra Dedhiya , Shashank Mahashabde , Yan Yang , Anshu Goel , Erhard Seiller , Bernhard Hauptmeier
IPC分类号： A61K31/136 , A61K31/13 , A61P25/00
CPC分类号： A61K31/13 , A61K9/0063 , Y02A50/411
摘要： The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.
摘要翻译： 本发明涉及药物化合物的制剂，例如具有抗微生物性质的环己胺和氨基金刚烷。 特别地，其涉及具有减少量的防腐剂的含水基制剂，其允许安全和方便的施用和柔性给药，并且在口服制剂的情况下，易于吞咽。 任选地，组合物包含提供必要的稳定性和保质期的组分，同时减少或避免组合物围绕容器封闭物的结垢，这导致泄漏和难以打开容器。
-
公开(公告)号：US20130012593A1
公开(公告)日：2013-01-10
申请号：US13618014
申请日：2012-09-14
申请人： Suneel K. Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Shashank Mahashabde
发明人： Suneel K. Rastogi , Niranjan Rao , Antonia Periclou , Wattanaporn Abramowitz , Mahendra G. Dedhiya , Shashank Mahashabde
CPC分类号： A61K31/13 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K47/38 , Y02A50/411
摘要： The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
摘要翻译： 本发明提供每天一次给药的药物组合物，其含有选自美金刚和美金刚的药学上可接受的盐中的至少一种治疗活性成分和药学上可接受的聚合物基质载体。 当所述形式进入使用环境时，当所述剂型暴露于水溶液时，本发明的剂型维持治疗活性剂的释放约4至约24小时，其中所述剂型具有 在进入所述使用环境之后经过约6小时至约12小时后，大于约80％。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.016 秒)
